OptimizeRx raises 2025 revenue guidance to $101M-$106M as subscription transition gains traction
Source: SeekingAlpha
2025-05-12 21:57:01 ET
More on OptimizeRx
- OptimizeRx Corporation (OPRX) Q1 2025 Earnings Call Transcript
- OptimizeRx Corporation (OPRX) Q4 2024 Earnings Call Transcript
- OptimizeRx Q1 2025 Earnings Preview
- OptimizeRx beats top-line and bottom-line estimates; initiates FY25 outlook
- Seeking Alpha’s Quant Rating on OptimizeRx
Read the full article on Seeking Alpha
For further details see:
OptimizeRx raises 2025 revenue guidance to $101M–$106M as subscription transition gains traction
OptimizeRx Corporation
NASDAQ: OPRX
OPRX Trading
0.65% G/L:
$6.15 Last:
311,923 Volume:
$6.01 Open:
OPRX Latest News
March 05, 2026 05:04:30 pm
UPDATE - OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
March 05, 2026 04:01:00 pm
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
OPRX Stock Data
$189,855,041
17,596,775
3.29%
31
N/A
Healthcare Providers & Services
Healthcare
US
Waltham
